Google Videos - Alternative Health
vHealth iPhone App Review
vHealth iPhone App Review https://itunes.apple.com/ca/app/vhealth/id610752363?mt=8 $FREE Receive discounted pricing on Natural Health
HubMed - Alternative Health
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.
Clinicoecon Outcomes Res. 2013; 5: 125-35
Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E
Paclitaxel albumin (nab-paclitaxel) is a nanoparticle albumin-bound paclitaxel formulation aimed at increasing therapeutic index in metastatic breast cancer. When compared to conventional paclitaxel, nab-paclitaxel has a reported longer time to progression, higher response, lower incidence of neutropenia, no need for premedication, shorter time of administration, and in pretreated metastatic breast cancer patients, extended overall survival. This study investigates the cost-effectiveness of nab-paclitaxel versus conventional paclitaxel for pretreated metastatic breast cancer patients in Italy.A Markov model with progression-free, progressed, and dead states was developed to estimate costs, outcomes, and quality adjusted life years over 5 years from the Italian National Health Service viewpoint. Patients were assumed to receive nab-paclitaxel 260 mg/m(2) three times weekly or conventional paclitaxel 175 mg/m(2) three times weekly. Data on health care resource consumption was collected from a convenience sample of five Italian centers. Resources were valued at Euro (€) 2011. Published utility weights were applied to health states to estimate the impact of response, disease progression, and adverse events on quality adjusted life years. Three sensitivity analyses tested the robustness of the base case incremental cost-effectiveness ratio (ICER).Compared to conventional paclitaxel, nab-paclitaxel gains an extra 0.165 quality adjusted life years (0.265 life years saved) and incurs additional costs of €2506 per patient treated. This translates to an ICER of €15,189 (95% confidence interval: €11,891-€28,415). One-way sensitivity analysis underscores that ICER for nab-paclitaxel remains stable despite varying taxanes cost. Threshold analysis shows that ICER for nab-paclitaxel exceeds €40,000 only if cost per mg of conventional paclitaxel is set to zero. Probabilistic sensitivity analysis highlights that nab-paclitaxel has a 0.99 probability to be cost-effective for a threshold value of €40,000 and is the optimal alternative from a threshold value of €16,316 onwards. Based on these findings, nab-paclitaxel can be considered highly cost-effective when compared to the acceptability range for ICER proposed by the Italian Health Economics Association (€25,000-€40,000).
Google Videos - far infrared therapy
Fall Asleep Under This Anti-Aging Panel, The New Far Infrared Rainbow
http://www.healinggrapevine.com/health-solutions/far-infrared/far-infrared-rainbow.html Portable Far infrared therapy and room heater makes ...
Videos
Acupuncture for Pets Is Proving Popular
 | please no haters. This is not my copyright just backup and sharing. I beg permission accident, American, case, country, crisis, demonstration, direct broadca... | Views: 0  0 ratings |
| Time: 02:16 | More in News & Politics |
Videos
Infrared sauna - Wiki Article
 | An infrared sauna uses infrared heaters to emit infrared radiant heat which is absorbed by the surface of the skin. Traditional saunas heat the body primary ... | Views: 1 0 ratings |
| Time: 03:09 | More in Education |
No comments:
Post a Comment